Login to Your Account

Sequella Inks $50M Licensing Deal for Tuberculosis Drug

By Catherine Shaffer

Tuesday, April 26, 2011
Powerful multidrug cocktails are critically important for battling multidrug-resistant tuberculosis (TB). Industry is working hard to develop new drugs that will not only work well individually, but synergistically, creating an effect where the whole is more than the sum of the parts.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription